Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
3.670
-0.010 (-0.27%)
Sep 10, 2024, 11:09 AM EDT - Market open
Soligenix Revenue
Soligenix had revenue of $2.34K in the quarter ending June 30, 2024, a decrease of -98.87%. This brings the company's revenue in the last twelve months to $494.62K, down -50.35% year-over-year. In the year 2023, Soligenix had annual revenue of $839.36K, down -11.55%.
Revenue (ttm)
$494.62K
Revenue Growth
-50.35%
P/S Ratio
5.99
Revenue / Employee
$32,975
Employees
15
Market Cap
8.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 839.36K | -109.55K | -11.55% |
| Dec 31, 2022 | 948.91K | 124.64K | 15.12% |
| Dec 31, 2021 | 824.27K | -1.54M | -65.07% |
| Dec 31, 2020 | 2.36M | -2.27M | -49.04% |
| Dec 31, 2019 | 4.63M | -611.53K | -11.67% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Innovative Eyewear | 1.53M |
| Mainz Biomed | 895.48K |
| Mangoceuticals | 866.79K |
| Bionomics | 451.25K |
| BioCardia | 428.00K |
| Eterna Therapeutics | 162.00K |
| Organovo Holdings | 73.00K |
SNGX News
- 7 days ago - Soligenix Receives European Patent for Improved Production of Synthetic Hypericin - PRNewsWire
- 25 days ago - Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 4 weeks ago - Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results - PRNewsWire
- 2 months ago - PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results - GlobeNewsWire
- 2 months ago - Soligenix stock rallies 400% on positive HyBryte trial results - Invezz
- 2 months ago - Crude Oil Down 1%; Soligenix Shares Surge - Benzinga
- 2 months ago - Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why - Benzinga
- 2 months ago - Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma - PRNewsWire